FGF23 in chronic kidney disease: are we lost in translation?
- 6 January 2016
- journal article
- Published by Portico in BoneKEy Reports
- Vol. 5, 770
- https://doi.org/10.1038/bonekey.2015.140
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Klotho Protects Against Indoxyl Sulphate-Induced Myocardial HypertrophyJournal of the American Society of Nephrology, 2015
- Biphasic Effects of Vitamin D and FGF23 on Human Osteoclast BiologyCalcified Tissue International, 2015
- The Effects of Cinacalcet in Older and Younger Patients on HemodialysisClinical Journal of the American Society of Nephrology, 2015
- FGF23 regulates renal sodium handling and blood pressureEMBO Molecular Medicine, 2014
- Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.JCI Insight, 2014
- FGF23 promotes renal calcium reabsorption through the TRPV5 channelThe EMBO Journal, 2014
- Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing DialysisThe New England Journal of Medicine, 2012
- Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytesJournal of Bone and Mineral Research, 2012
- FGF23 neutralization improves chronic kidney disease–associated hyperparathyroidism yet increases mortalityJCI Insight, 2012
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011